Co-Diagnostics, Inc. to Present at Sidoti Virtual Investor Conference
Co-Diagnostics, Inc. (NASDAQ: CODX) will present at the Sidoti Fall Virtual Investor Conference on September 23, 2021, at 3:15 p.m. EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Co-Diagnostics, Inc. (NASDAQ: CODX) will present at the Sidoti Fall Virtual Investor Conference on September 23, 2021, at 3:15 p.m. EDT. The presentation will be led by CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. Investors can access the event through the Co-Diagnostics website. Registration for the presentation and one-on-one meetings is available at www.sidoti.com/events.
Details
News Market Reaction – CODX
The recorded move for CODX in the trading session of this news was +2.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Sept. 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations, will present and host one-on-one meetings with investors at the Sidoti Fall Virtual Investor Conference.
The presentation will begin at 3:15 p.m. EDT on Thursday, September 23, 2021, and can be accessed on the Events and Webcasts section of the Co-Diagnostics website. To register for the presentation or one-on-ones, please visit www.sidoti.com/events.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-sidoti-virtual-investor-conference-301380863.html
SOURCE Co-Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.